Grossman Adam S 4

What Happened
Adam S. Grossman, President, CEO and Director of ADMA Biologics (ADMA), exercised options to acquire 15,000 shares at $5.40 per share (cost $81,000) on February 17, 2026, and sold a total of 21,000 shares in open market transactions that day at $16.08 per share (proceeds $337,680). The filing also reports a derivative disposition of 15,000 with a reported price of $0.00 (reported as a derivative transaction). The sales were executed under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: February 17, 2026.
• Exercise: 15,000 shares acquired at $5.40 each = $81,000 (code M).
• Sales: 15,000 shares sold @ $16.08 = $241,200; 6,000 shares sold @ $16.08 = $96,480; total sale proceeds = $337,680 (code S).
• Derivative disposition: 15,000 reported at $0.00 (code M) — reported separately in the filing.
• Plan: Sales were effected pursuant to a Rule 10b5‑1 trading plan entered Nov 14, 2025 (footnote F1).
• Holdings noted in footnotes: the filing lists 969,684 shares of common stock owned by Grossman and substantial unvested RSUs (about 1,314,695 unvested RSUs across multiple grants per F3–F5). An option grant from Feb 26, 2024 (underlying ~870,948 shares, with 217,737 vested on Feb 26, 2025) is described in footnote F8.
• Filing timing: filed on Feb 17, 2026 (no late filing indicated in this record).

Context

• This filing shows an options exercise and same‑day open‑market sales — a common pattern where exercised shares are sold (often to cover exercise cost/taxes or to monetize gains). The presence of a 10b5‑1 plan indicates the sales were preplanned.
• Derivative transactions reported at $0.00 typically reflect option/derivative-related dispositions reported separately on Form 4; the filing itself provides the official record but does not disclose management’s motives.